Conférences
le (25m33s)
Résultats de recherche
Trier par :
Nombre de programmes trouvés : 10522
Conférences
le (13m54s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Regulatory viewpoint (Yuki ANDO)
MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012:HEART FAILURE TRIALISTS WORKSHOPLEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALSChairpersons: Alexandre MEBAZAA, Paris, FRA - Christopher O’CONNOR, Durham, USAWebcast: Daniela DOBRE, Nancy, FRADecreasing the very high mortality and rate of re-hospitalization associated with acute worsening HF is one of the most important unmet needs in cardiovascular medicine. Despite positive signals in Phase II studies, no drug has proven to reduce the appallingly high mortality or readmission rates. The reasons for these ‘failed’ trials are multiple, including the adequacy of candidate drugs, dosing, patient selection and disease ... Voir la vidéo
Conférences
le (28m5s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : Treatment optimization (William T. ABRAHAM)
MODIGLIANI Debate Session 4 - Saturday December 1st, 2012:HEART FAILURE REMOTE MONITORING TRIALSChairpersons: Stefan ANKER, Berlin, GER - Ileana PIÑA, New York, USAWebcast: Daniela DOBRE, Nancy, FRACase studies and ultimate methodology for future trialsRemote monitoring remains an appealing option for following patients after a heart-failure hospitalization. Trials employing common strategies (simple phone calls with a nurse and Telemonitoring of vital signs) have in general not demonstrated improvement in survival and or reduction in risk of readmission; meta-analysis of telemonitoring trials using these common strategies, however, have shown improvements in survival and hospitalization rates. Recently, trials of more complex implanted remote ... Voir la vidéo
Conférences
le (12m13s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST (Michael FELKER)
MODIGLIANI Debate Session 5 - Saturday December 1st, 2012NOVEL DIURETIC STRATEGIES IN HEART FAILUREChairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITAWebcast: Patrick ROSSIGNOL, Nancy, FRA➢ Clinical congestion due to volume overload is the main cause of hospitalization for patients with HF and is an important therapeutic target. Failure to achieve effective and rapid correction of this condition in many patients hospitalized for HF results in prolongation of hospital stay and unfavorable after-discharge outcome.➢ Loop diuretics, though often effective for treating congestion, have significant limitations. Discovering ways to optimize exposure to loop diuretics, achieving effective decongestion while protecting ... Voir la vidéo
Conférences
le (33m23s)
Adolescence well being: risk and protective factors
Le laboratoire « Psychologie, Santé et Qualité de Vie » a profité de la rencontre à Bordeaux de plusieurs chercheurs spécialistes de l’adolescence pour présenter aux chercheurs, professionnels et étudiants, l’état de l’avancement de nos connaissances sur le développement des adolescents en tenant compte de ses multiples facettes et des multiples situations rencontrées par les adolescents qu’ils soient normaux, dans des filières d’excellence ou qu’ils soient susceptibles de s’engager dans des comportements à risque du fait d’une mauvaise régulation neuropsychologique des émotions et de l’activité ou de facteurs sociétaux. Parce que les transformations à l’adolescence se situent à l’interface entre les facteurs biologiques, psychologiques et sociétaux, les présentations des chercheurs tout au ... Voir la vidéo
Label UNT Conférences
le (4m14s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementInvestigator viewpoint: George BAKRIS, Chicago, USA - Ileana PIÑA, New York, USARegulatory viewpoint: Andrew FARB, FDA, USAIndustry viewpoint: Rob KIEVAL, CVRx, USA - Kenneth STEIN, Boston Scientific, USAAbstract : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementL’auteur n’a pas transmis de conflit ... Voir la vidéo
Label UNT Conférences
le (8m38s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementInvestigator viewpoint: George BAKRIS, Chicago, USA - Ileana PIÑA, New York, USARegulatory viewpoint: Andrew FARB, FDA, USAIndustry viewpoint: Rob KIEVAL, CVRx, USA - Kenneth STEIN, Boston Scientific, USAAbstract : What are relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval and reimbursement What kind of evidence is needed and the level is somewhat clear. Obviously, ... Voir la vidéo
Label UNT Conférences
le (4m2s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?
Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable.Should there be a position statement establishing rules for biomarker studies?John JARCHO, Boston, USA, NEJMRita REDBERG, San Francisco, USA, Arch Intern MedJoseph LOSCALZO, Boston, USA, CirculationJagat NARULA, New York, USA, JACC imagingMona FIUZAT, Durham, USA, JACC-HFJohn CLELAND, Hull, GBR, Former Eur J Heart FailureAbstract : Debate led by Journal Editors: There are too many studies and the quality is variable.Should there be a position statement establishing rules for biomarker studies?The measurement of biomarkers for diagnosis and prognosis ... Voir la vidéo
Label UNT Conférences
le (14m54s)
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries
Title : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countriesSpeaker: Prem PAIS, Bangalore, INDAbstract : India has a high prevalence of type 2 diabetes mellitus (DM) and the highest absolute number of diabetic people in the world – 50 million in 2006, estimated to increase to70 million by 2025. While there is no representative national survey, cross sectional studies in different parts of the country have demonstrated an increasing prevalence in both rural and urban areas of the country. An early survey done between 1972 -1975 on 35 000 subjects aged over 14 years reported ... Voir la vidéo
Label UNT Conférences
le (11m50s)
